Shanghai Bao Pharmaceuticals Co., Ltd. (02659.HK) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 20Aug 25Aug 28Sep 2Sep 7Sep 10Sep 15Sep 18

Key dataSep 18, 2026

OpenHKD 13.13

From 52W high−93.07%

Volume567900.00

Market capHKD 2.12B

P/E (TTM)—

P/S (TTM)—

Div yield—

Key dataSep 18, 2026

Open

HKD 13.13

From 52W high

−93.07%

Volume

567900.00

Market cap

HKD 2.12B

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

—

P/E (TTM)

—

RSI (14)

32.9

MomentumView details →

1D Return

+5.40%

YTD Return

−82.13%

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

—

EV/Sales

—

P/S (TTM)

—

P/B (TTM)

—

ProfitabilityView details →

Gross Margin

—

Net Margin

—

EBITDA Margin

—

ROE (TTM)

—

ROA (TTM)

—

Asset Turnover

—

GrowthView details →

Revenue YoY

—

EPS YoY

—

FCF YoY

—

Revenue CAGR 3Y

—

EPS CAGR 3Y

—

EBITDA YoY

—

MomentumView details →

1D Return

+5.40%

YTD Return

−82.13%

1Y Return

—

RSI (14)

32.9

vs 50D SMA

−17.16%

vs 200D SMA

—

Capital & dividendView details →

Debt/Equity

—

Current Ratio

—

Quick Ratio

—

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

−HKD 0.07

EPS Surprise

—

Beats (12Q)

—

Next Q EPS Est

—

Avg Surprise (4Q)

—

Rev Surprise

—

Financials snapshotView financials →

Revenue (TTM)

—

Net Income (TTM)

—

Op. CF (TTM)

—

Next earningsMar 26, 2027 →

Latest newsMore news →

Shanghai Baoye Pharmaceutical reported interim results for the six months ended June 2026, with revenue down 76.5% year-on-year to RMB 9.875 million and a narrowed net loss of RMB 154 million.23d ago

Similar companies

UroGen Pharma Ltd.URGN Sarepta Therapeutics, Inc.SRPT Trevi Therapeutics, Inc.TRVI Frontage Holdings Corporation01521.HK Antengene Corporation Limited06996.HK Palvella Therapeutics, Inc.PVLA Find similar companies →

Latest newsMore news →

Shanghai Baoye Pharmaceutical reported interim results for the six months ended June 2026, with revenue down 76.5% year-on-year to RMB 9.875 million and a narrowed net loss of RMB 154 million.23d ago